Previous 10 | Next 10 |
Passage Bio (PASG): Q3 GAAP EPS of -$0.63 beats by $0.13.Cash, cash equivalents and marketable securities of $335.7MPress Release For further details see: Passage Bio EPS beats by $0.13
– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to initiate in 1H21 – – Completion of...
PHILADELPHIA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, and Invitae (NYSE: NVTA), a leading medical genetics company, announce a collabo...
PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m...
The FDA has granted Orphan Drug and Rare Pediatric Disease ((RPD)) designations to Passage Bio's (PASG) PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy), a rare and often life-threatening lysosomal storage disease resulting in progressive damage to brain and peripheral...
PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orp...
The European Commission has designated Orphan Drug status to Passage Bio's (PASG) PBGM01 for the treatment of GM1 gangliosidosis (GM1)PBGM01, an adeno-associated virus-delivery gene therapy, and has previously been granted Orphan Drug and Rare Pediatric Disease designation in the U.S. for the...
PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that the European Commission (EC) has granted orphan drug design...
Passage Bio (PASG) announces publication of data in a murine model of GM1 gangliosidosis (GM1) demonstrating that a single intracerebroventricular injection of an optimized adeno-associated virus (PBGM01) into the cerebral spinal fluid ((CSF)) resulted in significant expression of Beta-g...
PHILADELPHIA, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced publication of data in a murine model of GM1 gangliosidosis (GM1...
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...